Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, MA, 02215, USA.
University Hospital Frankfurt, Department of Hematology/Oncology, Frankfurt/Main, Germany.
Br J Cancer. 2020 Apr;122(8):1121-1123. doi: 10.1038/s41416-020-0728-7. Epub 2020 Feb 4.
Targeted protein degradation has emerged as a strategy in cancer therapy. Yang et al. discovered that HBX19818, an inhibitor of the deubiquitinase (DUB) USP10, leads to the dual degradation of spleen tyrosine kinase (SYK) and FLT3, resulting in death of AML cells.
靶向蛋白降解已成为癌症治疗的一种策略。Yang 等人发现，去泛素化酶 (DUB) USP10 的抑制剂 HBX19818 导致脾酪氨酸激酶 (SYK) 和 FLT3 的双重降解，从而导致 AML 细胞死亡。
Zotero 插件